Posted by Michael Wonder on 23 Mar 2026
Enhertu approved in Japan as first tumour agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumours
23 March 2026 - Based on four Phase 2 trials where Enhertu demonstrated clinically meaningful responses across a broad range of tumours.
Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with HER2 positive (HER2 [ERBB2] gene amplification or immunohistochemistry 3+) advanced or recurrent solid cancers refractory or intolerant to standard treatments.
